Suppr超能文献

经皮注射类固醇治疗良性声带病变的长期疗效:一项前瞻性研究。

Long-term efficacy of percutaneous steroid injection for treating benign vocal fold lesions: A prospective study.

作者信息

Lee Seung Won, Park Ki Nam

机构信息

Department of Otolaryngology-Head and Neck Surgery, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.

出版信息

Laryngoscope. 2016 Oct;126(10):2315-9. doi: 10.1002/lary.25916. Epub 2016 Mar 12.

Abstract

OBJECTIVES/HYPOTHESIS: This study assessed the long-term efficacy and recurrence rates of percutaneous steroid injections (PSIs) for benign vocal fold lesions.

STUDY DESIGN

Prospective clinical study.

METHODS

A prospective human clinical trial was performed from October 2008 to September 2014 at Soonchunhyang University Hospital, Bucheon, Korea. Percutaneous steroid injection was performed in 84 consecutive patients with small benign vocal fold lesions, such as vocal fold nodules, polyps, and Reinke's edema, who could not be treated with voice therapy or surgery. Patients had acoustic aerodynamic, perceptual, stroboscopic, and voice handicap index evaluations before PSI and also 3, 6, 12, and 24 months after PSI.

RESULTS

Of the 84 patients, 37 (44.0%) showed complete remission; 22 (26.2%) showed partial remission; five (6%) had no response; and 20 (23.8%) developed recurrences after PSI. Most of the objective and subjective parameters that improved statistically (P < 0.05) 3 months after PSI remained stable until 24 months. For the recurrences, the average recurrence time interval after PSI was 8.5 ± 8.2 (range 3-36) months. Recurrence was associated with voice abuse after PSI and professional voice users (P < 0.05). Complications during follow-up included minimal vocal fold hematomas in 2.4% (2 of 84) and mild vocal fold atrophy in 1.2% (1 of 84).

CONCLUSION

Percutaneous steroid injection is a useful alternative modality for treating benign vocal fold lesions without morbidity. However, recurrence rates were higher with voice abuse after PSI and professional voice users.

LEVEL OF EVIDENCE

  1. Laryngoscope, 126:2315-2319, 2016.
摘要

目的/假设:本研究评估了经皮类固醇注射(PSI)治疗良性声带病变的长期疗效和复发率。

研究设计

前瞻性临床研究。

方法

2008年10月至2014年9月在韩国富川顺天乡大学医院进行了一项前瞻性人体临床试验。对84例连续的小型良性声带病变患者(如声带小结、息肉和任克氏水肿)进行经皮类固醇注射,这些患者无法通过嗓音治疗或手术治疗。患者在PSI前以及PSI后3、6、12和24个月进行声学空气动力学、感知、频闪喉镜和嗓音障碍指数评估。

结果

84例患者中,37例(44.0%)完全缓解;22例(26.2%)部分缓解;5例(6%)无反应;20例(23.8%)在PSI后复发。大多数在PSI后3个月有统计学改善(P<0.05)的客观和主观参数在24个月时保持稳定。对于复发患者,PSI后的平均复发时间间隔为8.5±8.2(范围3 - 36)个月。复发与PSI后嗓音滥用及职业用嗓者相关(P<0.05)。随访期间的并发症包括2.4%(84例中的2例)出现轻微声带血肿和1.2%(84例中的1例)出现轻度声带萎缩。

结论

经皮类固醇注射是一种治疗良性声带病变且无并发症的有用替代方法。然而,PSI后嗓音滥用及职业用嗓者的复发率较高。

证据水平

4。《喉镜》,126:2315 - 2319,2016年。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验